gbola amusa md cfa head hc research
sale trade et
viral news genet medicin disrupt chardan initi pasg
relat news march march pandem increasingli affect global
economi biotech space see myriad disrupt discuss march research eli
lilli unrat announc might prove lead indic biopharma compani initi respond
pandem lilli releas support view clearer risk biopharma stock relat new studi start
and/or exist studi enrol new patient multipl compani major clinic research institut
prvb qure sln gb chop anticip announc near-term
genet medicin space addit effort dna- rna-bas medicin
viru associ coronaviru diseas continu announc unrat
announc partnership olog bioservic privat manufactur dna vaccin mm
depart defens grant unrat announc develop inhal sirna
therapeut sanofi unrat unrat announc develop mrna vaccin
etherna immunotherapi privat also announc develop mrna vaccin global collabor
effort gate foundat biopharma compani agre share screen proprietari librari
molecular compound alreadi degre safeti activ data viru
highlight week march march chardan top pick partner novarti
unrat provid updat gene therapi gt program spinal muscular atrophi sma zolgensma
receiv posit chmp opinion europ demonstr sustain durabl year post dose
demonstr clinic meaning increas point hfmse score children age year
sma type believ week news support break-up thesi uniqur buy chardan top
pick announc achiev target dose patient phase hope-b trial gt
etranadez per march research vivo gt product etranadez benefit measur
futur visit even follow-up visit miss note hope-b trial rel insul current
major risk relat pandem initi coverag passag buy rate
potenti pipelin address major unmet need rare monogen disord central nervou system
look forward march april march et novarti unrat hold investor call discuss
new zolgensma data march proqr buy present find plan interim
analysi phase i/ii stellar trial adult usher syndrom non-syndrom retin pigmentosa
april buy ceo stphane bancel particip mit laboratori engin lfe
golub center financ polici gcfp distinguish lectur seri deal coronaviru industri
perspect follow compani report financi result unrat march
weekli price move chardan genet medicin vivo gene therapi ex vivo gene therapi
price move sinc februari impact chardan genet medicin vivo gt ex vivo
note measur impact februari broader market move march gm stock move
upcom chardan genet medicin event contact chardan rsvp
pleas refer import disclosur inform regul analyst certif found page report
gene express maintain clinic trial integr pandem
northwestern univers march publish viewpoint jama pandem pose threat
integr on-going random clinic trial author emphas unfortun realiti
mani trial involv suscept individu chronic diseas
consequ alreadi begun see delay and/or suspens clinic trial see relat news
although certain trial disrupt unavoid author propos solut may minim disrupt
preserv integr on-going random clinic trial ensur particip health safeti includ
priorit primari outcom temporarili elimin exploratori pre-specifi outcom modifi
protocol facilit collect altern self-report medic record data determin surrog
primari outcom collect questionnair via phone mail collect object outcom
walk test home off-sit exposur potenti infecti individu minim author
also propos accommod relat follow-up challeng due restrict includ continu
intervent medic beyond origin intend stop date follow-up test carri
particip still receiv intervent isol restrict lift
guidelin align recent fda issu guidanc also suggest altern method assess
addit safeti monitor still maintain clinic trial integr much possibl guidelin
creat disrupt mani trial potenti lead acceler timelin certain rare case exampl
axsom unrat announcedit acceler complet on-going phase ii/iii trial
alzheim diseas agit ensur safeti vulner patient popul pandem
maintain integr clinic trial compani expect top-lin result earli versu
prior guidanc overal public recent fda guidanc reinforc belief abil limit
physic intervent patient risk-mitig factor pandem continu
advoc own basket vivo vector gt compani aav-bas us rel
lower clinic trial disrupt risk compar therapi requir multipl treatment
intervent agtc buy buy chardan top pick qure buy chardan top pick
particular name advoc great potenti perform basket
buy news bad news extern march amusa
consid potenti extern adverum see good news believ clinic trial
involv aav-bas resili adverum alreadi complet dose cohort
optic phase trial wet also see risk mean age patient cohort
year mean extrem care mortal risk must taken undos patient cohort
march march share best perform vivo gt compani
best compani chardan genet medicin index see figur updat use februari
start accordingli rel call make share recent market movement maintain
convict buy rate share cheaper
buy time strike irrat trade amid macro backdrop march amusa
meiragtx buy chardan top pick march market close march market
close under-perform vivo vector gt peer nbi broader market
consequ despit premium fundament becam valu stock space
long ago albeit differ market condit meira peer acquir meira current
market cap nightstar mm audent bn
bn avexi bn feel big biopharma interest aav-bas gt greatli diminish recent week
buy ramif rel absolut posit march amusa
march buy report result provid biopsi result patient dose
vg/kg show microdystrophin fiber express normal
counterintuit concern materi delay solid competitor recruit clinic trial would
diminish competit disadvantag current clinic hold solid
pasg initi buy notch scienc provid safer passag gt march livshit
initi coverag passag buy rate potenti pipelin address unmet
need rare monogen disord access pre-emin scienc access rare diseas patient
use icm administr cgmp manufactur us increas likelihood passag succeed
page
note particular passag access extens expertis aav-bas gt collabor
univers pennsylvania gene therapi program gtp head passag co-found dr jim wilson
gtp expertis us reduc translat risk preclinical-stag program
ind file first pipelin candid anticip infantil gangliosidosi
ftd-grn krabb diseas program expect
clinic pois provid steadi flow clinic catalyst next month
buy strong zolgensma data make break-up thesi like march amusa
chardan top pick partner novarti unrat announc import posit zolgensma
sma name durabl benefit year post dose consist origin thesi
posit data older patient sma type suggest larger market opportun inde ahead
addit novarti state respons partial clinic hold program fda
octob avexi provid data indic clinic report sensori neuronopathi patient follow iv
treatment fda expect respond
believ set data start strong strengthen fundament around zolgensma thu
contribut break-up thesi highlight januari research buy
chardan top pick bn break-up stori
name analyst coverag lower relat risk march amusa
greater potenti perform pandem offer follow stock idea agtc buy
buy chardan top pick prvb buy newli chardan top pick qure buy chardan
top pick also advoc basket buy-rat microbiom name dddd ln
reduc exposur share price declin advoc own follow compani
valuat driven product complet near complet clinic trial basket
vivo vector gt compani product treatment whose benefit measur futur visit even
follow-up visit miss compani credibl platform whose valuat drop cash
time revers merger may increasingli relev ipo vehicl
vblt buy interim data suggest track march livshit
vbl announc phase oval trial interim analysi therapi ovarian cancer
met pre-specified biomark criterion absolut percentag advantag higher respons
rate treatment arm base dsmc review unblind data evalu patient
per compani respons rate among patient ssume balanc
random respons rate treatment arm addit weekli paclitaxel higher
discuss januari research phase ii studi similarli report respons
rate among evalu patient treat therapeut dose us provid encourag signal
respons phase may track seen phase ii
arbutu announc interim data phase ia/ib clinic trial evalu lead asset treatment
chronic hepat hbv releas includ data healthi subject part subject chronic hepat
 part treat singl dose
believ interpret data part first requir cogniz number import caveat
sampl size small mg mg mean baselin hbsag level significantli lower
mg patient iu/ml mg patient iu/ml mg patient hbeag-
neg mg patient competit rnai develop effort report
multi-dos patient data direct comparison singl dose data possibl
believ initi data warrant evalu indic next step compani
continu follow hbv patient mg dose cohort week compani also intend
enrol new cohort hbv patient dose mg
press releas highlight fiscal result neubas manag reiter announc
week march preclin data peptid nucleic acid pna -base antisens oligonucleotid patrol
compound demonstr pk/pd properti anim model human cell
believ compani initi focu repeat expans disord correct strategi abil
deliv pna therapeut intraven would signific advantag deeper review scienc replay
march chardan-host leadership call neubas avail
page
genet medicin news march march
neutral confirm busi continu strateg prioriti march
privat appoint dr juli krop march
trvx unrat announc rsu give insid right subscrib share nok march
ise unrat appoint dr pravin dugel evp chief strategi busi offic march
fbio unrat announc mm seri cumul prefer stock repurchas program march
carisma privat announc public natur biotech car-m immunotherapi march
carisma collabor univers pennsylvania engin human macrophag
chimer antigen receptor construct goal circumv challeng encount -t therapi
solid tumor includ limit cell infiltr solid tumor type suppress signal
cell type within tumor microenviron
car-m engin adenovir vector effici kill tumor cell phagocytosi vitro reduc tumor
burden mous tumor model lead longer surviv importantli cytokin signal releas car-
ms promot pro-inflammatori tumor microenviron includ suppress bystand macrophag
carisma current advanc car-m candid target preclin studi
mani open question remain car-m detail mechan optim dose combin potenti see
technolog differenti approach promot immun activ difficult-to-treat solid tumor
unrat appoint dr damien mcdevitt ceo march
unrat announc licens agreement unrat mxct advanc allogen car-t march
etherna immunotherapi privat announc consortium develop mrna vaccin march
unrat announc fda track design frontotempor dementia march
nv unrat announc data show meaning respons patient sma type march
nv unrat announc zolgensma data show clinic meaning benefit sma march
unrat announc partnership olog bioservic privat produc vaccin march
gnpx unrat appoint new member board director march
cyad unrat announc result provid busi updat march
sln gb unrat announc mm invest unrat azn develop sirna therapeut march
buy announc agreement privat ila distribut onpattro turkey march
genesi privat announc name chang cg oncolog march
recod privat announc mm seri financ march
unrat provid assess impact busi oper march
bluebird bio announc anticip bla file autolog car-t therapi ide-cel multipl myeloma
partnership unrat bristol-my squibb remain track
due disagr fda regard time provid inform releas assay well
likelihood disrupt compani anticip complet roll bla submiss
lentiglobin -thalassemia bluebird prior guidanc februari
regulatori delay could allow earlier-stag clinic program sangamo therapeut unrat /sanofi
unrat crispr buy /vertex pharmaceut unrat gain ground though program
could also point show exposur broader delay affect biotech space
qure buy announc achiev target patient dose phase hope-b trial etranadez march
uniqur buy chardan top pick announc complet dose target goal patient
pivot phase trial patient dose target gt treatment hemophilia
compani expect top-lin data hope-b support bla submiss
page
uniqur also announc postpon initi dose patient phase i/ii trial huntington
diseas due pandem cours delay potenti upsid describ
januari research uniqur could achiev sarepta unrat -like valuat alon uniqur
succe phase i/ii huntington diseas trial
bntc unrat announc result scheme meet re-domicil us march
harvard univers publish scienc engin crispr variant broad target capac march
unrat announc posit interim data phase ii trial hpv anal dysplasia march
buy address busi continu respons pandem march
unrat announc pediatr diseas design cf anticip delay march
phio unrat announc result provid busi updat march
unrat announc result provid busi updat march
unrat provid busi updat respons pandem march
unrat announc partnership unrat sni develop mrna vaccin march
nv unrat announc posit chmp opinion zolgensma sma march
unrat announc licens agreement unrat tak advanc gt rare disord march
unrat provid busi updat respons pandem march
ucsd publish scienc advanc effect biomimet sirna nanodeliveri system march
compani mention report
page
page
select catalyst genet medicin coverag
lumasiran report top-line result illuminate-a trial primari hyperoxaluria type
nedosiran report multi-dos data phyox open-label trial primari hyperoxaluria
lunar-otc file ind ornithin transcarbamylas over-the-counter defici
dose patient clear cell renal cell carcinoma
zolgensma anticip approv eu sma
pre-submiss meet ema
xlrp end-of-phas ii meet fda xlrp
nedosiran complet enrol trial primari hyperoxaluria
report addit process data fanconi anemia
submit ind diabet retinopathi
aro-enac file cta cystic fibrosi
present initi clinic data cardiovascular diseas
initi long-term follow-up initi patient phase i/ii studi batten diseas
b-vec initi pivot phase trial deb
report top-line interim result phase i/ii poc trial arci
nomin develop candid
initi phase ib studi liver kidney transplant recipi cscc
select lead product candid
complet assess cohort phase i/iia trial wet
suprachoroid initi phase ii trial wet use microinjector
suprachoroid submit ind phase ii trial dr use microinjector
report data secondari endpoint expand cohort phase i/ii hofh
zolgensma anticip approv japan sma
complet enrol phase i/ii pioneer trial retin pigmentosa
initi investigator-initi phase ii studi recurr glioblastoma
givosiran report addit result envison trial acut hepat porphyria
report phase data hypertriglyceridemia
report phase data dyslipidemia
aro-aat report biopsi data phase ii open label studi antitrypsin defici
report updat data phase i/ii trial pku announc expans cohort dose
provid updat guidanc phase i/ii trial initi time fda discuss
submit ind attr
report result phase ii nivolumab combin studi skin cancer cohort
provid interim data cohort phase i/ii trial mp ii
provid program updat preclin develop diseas
figur dicerna krystal expect import data read-out
page
select catalyst genet medicin coverag
report interim analysi phase ii trial cmv
report top-line result phase reflect trial lhon
report top-line result realiti observ natur histori studi lhon
submit ema lhon
report top-line result cohort phase i/ii pioneer trial retin pigmentosa
report multipl dose data chronic hepat infect
initi phase i/ii trial diabet retinopathi
present data phase optic studi wet
report data phase i/ii trial
xlrp report interim analysi group mo data group pi/ii trial xlrp
dose patient phase i/ii trial antitrypsin defici
report initi data phase i/ii studi batten diseas
b-vec initi clinic studi eu deb
initi dose patient clinic studi attr
report initi phase data danon diseas
report updat data phase i/ii trial lad-i
report preliminari phase data pyruv kinas defici
report preliminari phase ii data fanconi anemia
submit ind diseas
initi pivot trial subretin deliveri wet
suprachoroid initi phase ii trial dr use microinjector
suprachoroid interim data cohort wet w/ microinjector
submit bla fda lhon
program file ind oncology/inflammatori indic
lumasiran potenti fda/ema approv primari hyperoxaluria type
etranadez report top-line data pt pivot phase hope-b studi hem
zolgensma anticip approv switzerland canada australia sma
xlrp initi pivot phase trial xlrp
present initi proof concept data clear cell renal cell carcinoma
present stage data gangliosidosi
complet adult low mid-dos cohort
file ind sickl cell diseas
report result phase studi less ici respons tumor
report result phase ii nivolumab combin studi multipl solid tumor
report result monotherapi studi liver kidney transplant recipi cscc
initi pivot phase trial retin pigmentosa
report data nci trial combin checkpoint inhibitor gi cancer
initi piii studi hypertriglyceridemia
initi piii studi dyslipidemia
report addit data phase i/ii trial hemoglobinopathi
report initi data phase i/ii trial b-cell malign
submit ind file hemophilia
vy-aadc present result trial result trial pd
figur regenxbio replimun uniqur expect import data read-out
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ benitec biopharma
biomarin lysogen oxford biomedica neutral vbl buy
figur week end genet medicin vivo gt ex vivo gt ge srna mrna
page
week-over-week perform chardan genet medicin vivo gene therapi ex vivo gene therapi gene edit srna mrna basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap gene therapyvectortickerratingccm ptupsideclosechang changemc mm voyag genet n-f gene therapi exclud i/o vectortickerratingccm ptupsideclosechang changemc mm orchard editingtechnologytickerratingccm ptupsideclosechang changemc mm precis therapytechnologytickerratingccm ptupsideclosechang changemc mm arcturu pharmaceut
corpor report factset chardan note mention stock unrat unless state select public gm compani includ benitec biopharma
biomarin lysogen oxford biomedica neutral vbl buy
figur vs feb genet medicin vivo gt ex vivo gt ge srna mrna
page
chardan genet medicin vivo gene therapi ex vivo gene therapi gene edit srna mrna basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap gene therapyvectortickerratingccm ptupsideclosechang changemc mm homolog medicinesaav n-f genet gene therapi exclud i/o vectortickerratingccm ptupsideclosechang changemc mm mustang editingtechnologytickerratingccm ptupsideclosechang changemc mm intellia therapytechnologytickerratingccm ptupsideclosechang changemc mm pharmaceut
corpor report factset chardan note avx bold nite static market cap contribut post acquisit includ reflect valu creation within sector
figur public genet medicin vivo gt ex vivo gt gene edit srna mrna therapi companiesend-monthli market cap select compani januari present
page
cap million chardan genet medicin ivgt evgt ge srna/mrna monthli sector pharmaceut
corpor report factset chardan note avx bold nite static market cap contribut post acquisit includ reflect valu creation within sector ise
ly pa oxb ln exclud due either modest size and/or histor non-vector-gt and/or ex vivo gt exposur confound analys vivo gt sector valuat
figur public vivo gene therapi companiesend-monthli market cap select compani januari present
page
cap million vivogen therapi monthli sector valuationabeoadvmagtcavxsboldfixxkrysmgtxniteonceprvlqurergnxsight-parsldbvygr pharmaceut
figur public ex vivo gene therapi companiesend-monthli market cap select compani januari present
page
cap million ex vivogen therapi monthli sector valuationavrobluembioortxrubi pharmaceut
figur public gene edit companiesend-monthli market cap select compani januari present
page
cap million gene edit monthli sector valuat pharmaceut
corpor report factset chardan atrx bntc rgl sln ln exclud due modest size
figur public srna mrna therapi companiesend-monthli market cap select compani januari present
page
cap million srna mrna therapi monthli sector valuationabusalnyarctarwrbntxdrnamrnatbio pharmaceut
vivo gene therapi comp krystal meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name ise model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public vivo gene therapi companiesw prefer buy buy buy qure buy greater potenti drive upsid space
page
targettargetccmpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog medicinesfixxbuyaav n-f pharmaceuticalsrcktbuyaav privat vivogt compani molecular akouo ask cardiac inhibitor estev freelin gener horama stride tamid taysha gene therapi tenaya vivet note marin lysogen ultragenyx addit unrat public compani genethon relev non-profit organ pharmaceut
gene edit comp see greater upsid potenti intellia
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name cll model current market cap
figur gene editingw broadli expect out-performance crispr gene edit sector higher potenti perform buy
page
targettargetccmpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof privat gene edit companiescarib scienc egenesi emendo therapeut excis mammoth scienc myogen poseida recombinet spotlight trucod gene repair verv technolog pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
price prv
figur prioriti review voucher prv sold million million
page
date fda rpdd
ultragenyx genetx
retin pigmentosa exon mutat
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
ftd grn mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
